goserelin
Commercial- Indications
- Prostate cancer, Endometriosis
Company intelligence / Profile preview
메디포럼제약
서울특별시 성동구 성수동2가 / 경기 군포시 당동 등지에 사업장 존재[2][3], 대한민국(Korea)phrma.org ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Commercial
01
Overview
(주)메디포럼제약은 펩타이드 원천기술을 기반으로 희귀질환 치료제(씨트렐린구강붕해정), 치매치료제(엑셀씨캡슐 등)를 상용화했으며, 약물전달시스템(DDS)을 이용한 중추신경계(CNS) 및 항암 신약 파이프라인을 보유하고 있다. 주요 신약 후보(PM012)는 알츠하이머병 임상2b/3상 단계에 있다[5][6].
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- PeptidesSmall moleculesHerbal/natural products
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
'LSK글로벌파마서비스' – 임상시험 수탁기관 계약'아주대학교' – 임상 및 학술 협력
Beyond the preview
Go deeper on 메디포럼제약.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 메디포럼제약.